-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Eiger BioPharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2012 to 2023.
- Eiger BioPharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2023 was $683K, a 62.9% decline year-over-year.
- Eiger BioPharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2023 was $5.01M, a 39.8% decline year-over-year.
- Eiger BioPharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $5.01M, a 39.8% decline from 2022.
- Eiger BioPharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $8.32M, a 5.27% increase from 2021.
- Eiger BioPharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $7.9M, a 32.3% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)